Karl-Franzens-University Graz, Inst. Pharm. Sciences, Schubertstrasse 1, 8010 Graz, Austria.
BIT Pharma, Leonhardstrasse 109, 8010 Graz, Austria.
Biomolecules. 2021 Jan 12;11(1):91. doi: 10.3390/biom11010091.
The recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, the cause of coronavirus disease (COVID-19) and the associated ongoing pandemic, frequently leads to severe respiratory distress syndrome and pneumonia with fatal consequences. Although several factors of this infection and its consequences are not completely clear, the presence and involvement of specific chemokines is undoubtedly crucial for the development and progression of COVID-19. Cytokine storm and the often-resulting cytokine release syndrome (CRS) are pathophysiological hallmarks in COVID-19 infections related to its most severe and fatal cases. In this hyperinflammatory event, chemokines and other cytokines are highly upregulated and are therefore not fulfilling their beneficial function in the host response anymore but causing harmful effects. Here, we present the recent views on the involvement of chemokines and selected cytokines in COVID-19 and the therapeutics currently in clinical development targeting or interfering with them, discussing their potentials in the treatment of COVID-19 infections.
最近发现的严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)病毒是导致冠状病毒病(COVID-19)和相关持续大流行的病原体,经常导致严重的呼吸窘迫综合征和肺炎,并导致致命后果。尽管这种感染及其后果的几个因素尚不完全清楚,但特定趋化因子的存在和参与对于 COVID-19 的发展和进展无疑是至关重要的。细胞因子风暴和由此产生的细胞因子释放综合征(CRS)是与 COVID-19 感染相关的最严重和致命病例的病理生理学特征。在这种超炎症事件中,趋化因子和其他细胞因子高度上调,因此不再发挥其在宿主反应中的有益功能,而是产生有害影响。在这里,我们介绍了趋化因子和选定细胞因子在 COVID-19 中的作用以及目前正在临床开发中针对它们或干扰它们的治疗方法,讨论了它们在 COVID-19 感染治疗中的潜力。